ClinicalTrials.gg
RecruitingNCT07660341Updated Jul 8, 2026

SAD Study of CGB3002 in Healthy Participants

A Phase 1 interventional study of CGB3002 0.08 mg/kg and CGB3002 0.4 mg/kg in Alzheimer s Disease, sponsored by ChainGen Biopharma Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by ChainGen Biopharma Ltd · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Alzheimer Disease with a site in Australia — 23 open to participants now, 42 under way, 18 of them phase 3. Alzheimer Disease · Australia.

Planned enrollment
140th of 168
46 · median 313
Started
2026
with 7 others
Phase 1
27 of 177
4 open now
Primary completion
2027-04
later than 13 of 41 live
Registered
173rd of 177
by date

Among the 177 studies in Alzheimer Disease with a site in Australia, this one is the 140th largest by planned enrollment of the 168 interventional ones that give a count, is one of 8 that started in 2026, is one of 27 in phase 1, reaches primary completion later than 13 of the 41 other live ones, and was the 173rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

23 of the 177 studies in Alzheimer Disease with a site in Australia are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Alzheimer Disease with a site in Australia, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single ascending IV doses of CGB3002 in healthy participants. CGB3002 is being developed to treat Alzheimer's Disease.

Read the detailed description

This study includes 5 planned sequential cohorts. Participants will be randomized to receive a single IV dose of CGB3002, active comparator or placebo, with doses administered in ascending order. Based on the emerging data, there will be options to adjust the number of participants on active or placebo per subsequent dose level, and doses may be repeated or adjusted based on safety, tolerability and plasma pharmacokinetic data. Optional cohorts may be added to evaluate an intermediate dose level or to expand the dose level by SRC.

03

Conditions studied

  • Alzheimer s Disease

Browse trials for

Keywords

  • CGB3002
  • Healthy participants
  • Australia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have signed written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
  • Age≥18 years and\<55 years at the time of consent, healthy participants, male or female.
  • A (BMI) of 18 to 32 kg/m2 (cutoff inclusive), with male participants weighing no less than 50 kg, female participants weighing no less than 40 kg.
  • Males and females of agree to have no plans for childbearing, use reliable measures and not to donate sperm or ova from 30 days prior to dosing until 120 days after dosing. For females of childbearing potential, hormonal contraceptives should begin at least 1 month prior to screening to ensure contraceptive is in full effect.

Exclusion criteria

Exclusion Criteria:

  • A known history of drug allergy or atopic allergic disease (asthma, urticaria, eczematous dermatitis) or a known history of allergy to biologics or any in biologics, fully resolved childhood asthma can be enrolled.
  • Any disease that may affect the safety evaluation of the participants or the in vivo process of the product, including the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematopoietic system, metabolic endocrine system, etc.
  • Use of prescription drugs within 14 days or five half-lives (whichever is longer) prior study drug administration, unless determined by the Investigator and Sponsor to be non-interfering (e.g., hormonal ).
  • Use of over-the-counter (OTC) or Chinese herbal medicine within 7 days or 5 half-lives (whichever is longer) prior to study drug administration, unless determined by the Investigator and Sponsor to be non-interfering.
  • With a history of drug abuse within 12 months prior to dosing.
  • Cannot tolerate punction, have a history of needle fainting or blood fainting.
  • Have participated in clinical trials, whether for drugs or medical devices, within 30 days prior to administration or within 7 times the known elimination half-life, whichever is longer.
  • Blood donation or significant blood loss (> 300 mL) within 30 days prior to dosing, and planning to blood donate during the study.
  • Any vaccinations with a (excluding influenza vaccine) within 60 days prior to dosing.
  • (AST) or alanine aminotransferase (ALT) ≥1.5× at screening or Day -2. Total (TBIL) > ULN at screening or Day -2(except in those due to findings consistent with Gilbert's disease).
  • Estimated \< 80 mL/ min (Cockroft-Gault equation) at screening or Day-2.
  • Test positive for syphilis, virus surface antigen (HbsAg), hepatitis B core antibody (HBcAb), virus antibody (HCV-Ab) or antibody at screening.
  • Urine drug screening positive at screening or Day-2.
  • Have a head MRI demonstrating either cerebral microhemorrhages, or superficial siderosis, or prior evidence of microhemorrhage, or any other major intracranial pathology.
  • Still needed or planned to engage in vigorous physical activity or exercise during study participation.
  • Other conditions deemed inappropriate by the investigator to participate in the clinical trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Cohorts 1-5 each has 2 participants who will receive placebo, 10 in total.

    Drug: Placebo

  • Active comparator
    Active Comparator

    Cohorts 1-5 each has 2 participants will receive active comparator, 10 in total.

    Drug: Comparator Drug

  • Experimental
    CGB3002 0.08 mg/kg

    Healthy participants will be administered a single intravenous dose of CGB3002 (0.08 mg/kg).

    Drug: CGB3002 0.08 mg/kg

  • Experimental
    CGB3002 0.4 mg/kg

    Healthy participants will be administered a single intravenous dose of CGB3002 (0.4 mg/kg).

    Drug: CGB3002 0.4 mg/kg

  • Experimental
    CGB3002 1.2 mg/kg

    Healthy participants will be administered a single intravenous dose of CGB3002 (1.2 mg/kg).

    Drug: CGB3002 1.2 mg/kg

  • Experimental
    CGB3002 3.6 mg/kg

    Healthy participants will be administered a single intravenous dose of CGB3002 (3.6 mg/kg).

    Drug: CGB3002 3.6 mg/kg

  • Experimental
    CGB3002 7.2 mg/kg

    Healthy participants will be administered a single intravenous dose of CGB3002 (7.2 mg/kg).

    Drug: CGB3002 7.2 mg/kg

Interventions

  • DrugCGB3002 0.08 mg/kg

    Cohorts 1: healthy participants will be administered a single intravenous dose of CGB3002 at dose level of 0.08 mg/kg.

  • DrugCGB3002 0.4 mg/kg

    Cohorts 2: healthy participants will be administered a single intravenous dose of CGB3002 at dose level of 0.4 mg/kg.

  • DrugCGB3002 1.2 mg/kg

    Cohorts 3: healthy participants will be administered a single intravenous dose of CGB3002 at dose level of 1.2 mg/kg.

  • DrugCGB3002 3.6 mg/kg

    Cohorts 4: healthy participants will be administered a single intravenous dose of CGB3002 at dose level of 3.6 mg/kg.

  • DrugCGB3002 7.2 mg/kg

    Cohorts 5: healthy participants will be administered a single intravenous dose of CGB3002 at dose level of 7.2 mg/kg.

  • DrugPlacebo

    Healthy participants will be administered a single intravenous dose of matching placebo.

  • DrugComparator Drug

    Healthy participants will receive a single intravenous dose of the comparator drug at the same dose level as CGB3002.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events as a Measure of Safety and Tolerability

    Safety assessment variables will include all adverse events (AEs) including AEs, physical examinations, neurological examinations, vital sign measurements, electrocardiograms, laboratory parameters.

    Time frame: up to Day 15 weeks.

Secondary outcomes

  1. PK of CGB3002: Maximum Concentration (Cmax)

    Cmax after single intravenous infusion of CGB3002 based on non-compartmental analysis.

    Time frame: up to 8 weeks

  2. PK of CGB3002: time attain to Cmax (Tmax)

    Tmax after single intravenous infusion of CGB3002 based on non-compartmental analysis.

    Time frame: up to 8 weeks

  3. PK of CGB3002: Apparent terminal half-life (T1/2)

    T1/2 after single intravenous infusion of CGB3002 based on non-compartmental analysis.

    Time frame: up to 8 weeks

  4. PK of CGB3002: Area under the plasma concentration versus time curve from zero to t h post-dose (AUC0-t)

    AUC0-t after single intravenous infusion of CGB3002 based on non-compartmental analysis.

    Time frame: up to 8 weeks

  5. PK of CGB3002: Area under the plasma concentration versus time curve extrapolated to infinity (AUC0-inf)

    AUC0-inf after single intravenous infusion of CGB3002 based on non-compartmental analysis.

    Time frame: up to 8 weeks

  6. PK of CGB3002: the total body clearance (CL)

    CL after single intravenous infusion of CGB3002 based on non-compartmental analysis.

    Time frame: up to 8 weeks

  7. PK of CGB3002: Volume of distribution during the terminal phase (Vz)

    Vz after single intravenous infusion of CGB3002 based on non-compartmental analysis.

    Time frame: up to 8 weeks

  8. Concentration ratio of CSF to plasma

    CSF concentrations were measured by a specific and validated method. Concentration ratio of CSF to plasma on Day 3 post dose will be calculated.

    Time frame: Day 3

  9. Incidence of anti-CGB3002 antibodies (ADAs)

    For each dose group, the numbers and proportions of participants who were positive or negative for anti-drug antibodies (ADA) at baseline (baseline prevalence) and after study drug administration (post-baseline incidence during the treatment and follow-up periods) were summarized.

    Time frame: up to 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 10 months is below that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07660341
Lead sponsor
ChainGen Biopharma Ltd
Collaborators
ChainGen Biopharma (Australia) Pty Ltd
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 30, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Jul 8, 2026

Study contacts

Ofer Gonen, M.D.
Contact
o.gonen@nucleusnetwork.com.au
(03) 8593 9801
Zhizheng Zhang, M.D.
study director · ChainGen Biopharma Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion